American Journal of Psychiatry

Article	Citations
Broadening the Parameters of Clinical High Risk for Psychosis	504
2024 Annual Meeting: Presidential Address	218
Genes To Mental Health (G2MH): A Framework to Map the Combined Effects of Rare and Common Variants on Dimensions of Cognition and Psychopathology	151
Evaluating Associations Between Cannabis and Heroin Use	142
Treating Pathologies of the Will	134
Integrating Clinical and Basic Research: Opioid Use Disorder, Psychotic Illnesses, and Prefrontal Microcircuits Relevant to Schizophrenia	125
Mental Health Disparities Research: An Introduction to New Directions	120
Highlights From the Residents’ Journal: December 2021	117
Brain-Based Biotypes of Psychiatric Vulnerability in the Acute Aftermath of Trauma	116
Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosi	107
20-Year Prospective, Sequential Follow-Up Study of Heterogeneity in Associations of Duration of Untreated Psychosis With Symptoms, Functioning, and Quality of Life Following First-Episode Psychosis	99
Future of Sensorimotor and Psychomotor Dysfunction in Mental Disorders: Emerging Tools, Methodological Challenges, and the Road Ahead	99
Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?	97
A New Agenda for Optimizing Investments in Community Mental Health and Reducing Disparities	94
A Call to Psychiatrists: Deprescription of Unnecessary Anticholinergic Medications in Schizophrenia Must Start Now	94
Intentional Drug Overdose Deaths in the United States	94
Neural Signatures of Pain Modulation in Short-Term and Long-Term Mindfulness Training: A Randomized Active-Control Trial	91
From Scanner to Bedside: Building Bridges in Translational Psychiatric Neuroimaging	88
Cannabis and Brain Health: What Is Next for Developmental Cohort Studies?	88
Can Neuromelanin-Sensitive MRI Provide Insight Into the Dopaminergic Pathways Contributing to Substance Use?	85
Depression, Inflammation, and Postpartum Psychosis	84
From Prediction to Action: Moving Beyond Machine Learning to Implementing Evidence-Based Perinatal Mental Health Care	83
Project Harmony: A Meta-Analysis With Individual Patient Data on Behavioral and Pharmacologic Trials for Comorbid Posttraumatic Stress and Alcohol or Other Drug Use Disorders	82
On the Genetic and Environmental Relationship Between Suicide Attempt and Death by Suicide	79
New Insights Into Psychotic Disorders	75

Trends in Prescription Stimulant, Opioid, and Benzodiazepine Use and Diversion in U.S. Adolescents	74
Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression	73
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression	70
Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	70
Highlights From the Residents’ Journal: September 2021	67
2024 Annual Meeting: CEO and Medical Director’s Address	67
Correcting Overestimations in Self-Harm Visit Data	65
APA Council Reports	62
Highlights From the Residents’ Journal: September 2024	61
Corrigendum to Morley et al.	59
Older Adults are at Heightened Risk of the Effects of Cannabis Use: Response to Walaszek	59
Correction to Poirot et al.	59
Coordinate Network Mapping: An Emerging Approach for Morphometric Meta-Analysis	59
Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al.	58
Suicide and the Menstrual Cycle	56
The First Large GWAS Meta-Analysis for Postpartum Depression	54
Familial Risk of Postpartum Psychosis	53
Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population	53
Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden	53
Characterizing the Most Vulnerable Prefrontal Cortical Neurons in Schizophrenia	52
Back to the Future: Esmethadone, the (Maybe) Nonopiate Opiate, and Depression	51
Early Adversity and Development: Parsing Heterogeneity and Identifying Pathways of Risk and Resilience	51
Neural Responses to Intranasal Oxytocin in Youths With Severe Irritability	51
12-month Prevalence Estimates of Substance Use Disorders Using DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use	51
Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial	48
Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder	48
Sexual Identity Continuity and Change in a U.S. National Probability Sample of Sexual Minority Adults: Associations With Mental Health and Problematic Substance Use	47
Proof-of-Principle Study on ECT Illustrates Challenges and Possible Merits of Using Polygenic Risk Scores to Predict Treatment Response in Psychiatry	47
Points that Need Attention in Early Auditory Information Processing Research in Schizophrenia: Response to Lin and Hsieh	47
Rebecca W. Brendel, M.D., J.D., 149th President, 2022–2023	46
From Crisis to Action: Psychiatry’s Ethical Imperative to Defend Transgender People’s Rights, Dignity, and Access to Care	45
The Safety of Pimavanserin for Parkinson’s Disease and Efforts to Reduce Antipsychotics for People With Dementia	45
Comment on “Elevated C-Reactive Protein in Patients With Depression, Independent of Genetic, Health, and Psychosocial Factors: Results From the UK Biobank”	45
Scientific Advances Relevant to Schizophrenia, Psychosis, and the Treatment of Methamphetamine Use Disorder	45
Risk of Incident Psychosis and Mania With Prescription Amphetamines	44
Genetic and Environmental Contribution to the Co-Occurrence of Endocrine-Metabolic Disorders and Depression: A Nationwide Swedish Study of Siblings	43
Sustained Efficacy of Stanford Neuromodulation Therapy (SNT) in Open-Label Repeated Treatment	43
Predictive Value of Acute Neuroplastic Response to rTMS in Treatment Outcome in Depression: A Concurrent TMS-fMRI Trial	42
Associations Between a Primary Care-Delivered Alcohol-Related Brief Intervention and Subsequent Opioid-Related Outcomes	42
Aberrant Developmental Patterns of Gamma-Band Response and Long-Range Communication Disruption in Youths With 22q11.2 Deletion Syndrome	40
Shared and Specific Neural Correlates of Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder: A Meta-Analysis of 243 Task-Based Functional MRI Studies	39
Alcohol and the Etiology of Depression	39
The Neglected Role of Psychotherapy for Treatment-Resistant Depression	39
Ketamine for Depression, but at What Cost? A Review of Ketamine’s Neurotoxic Effects From Preclinical and Human Studies	38
2021 Articles of Import and Impact	36
Suicide in Black Females	36
Slowly Working Toward More Treatments for Depression in Bipolar II Disorder	35
What Do Four Decades of Research Tell Us About the Association Between Childhood Adversity and Psychosis: An Updated and Extended Multi-Level Meta-Analysis	35
Synaptic Variability and Cortical Gamma Oscillation Power in Schizophrenia	35
Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder	35

Psilocybin: From Psychiatric Pariah to Perceived Panacea	34
Reduction in Trauma-Related Symptoms After Anesthetic-Induced Intra-Operative Dreaming	34
Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary	34
Double-Blind, Sham-Controlled Randomized Trial Testing the Efficacy of fMRI Neurofeedback on Clinical and Cognitive Measures in Children With ADHD	33
Neural Correlates of Stress and Alcohol Cue-Induced Alcohol Craving and of Future Heavy Drinking: Evidence of Sex Differences	33
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression	33
Neuromodulation Strategies for the Treatment of Depression	33
Predicting Acute Changes in Suicidal Ideation and Planning: A Longitudinal Study of Symptom Mediators and the Role of the Menstrual Cycle in Female Psychiatric Outpatients With Suicidality	32
Treatment Response Prediction in Major Depressive Disorder Using Multimodal MRI and Clinical Data: Secondary Analysis of a Randomized Clinical Trial	32
The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders	32
Diagnosing Prescription Opioid Use Disorder in Patients Using Prescribed Opioids for Chronic Pain	31
Correction to Baum et al.	30
Keeping Track and Providing Tools for Future Crisis Management: Suicide Attempt and Self-Harm Presentations at Emergency Departments	30
Drug Cues Trigger Corticolimbic Hyperreactivity in Heroin Users	30
Toward Precision Noninvasive Brain Stimulation	30
Can Smartphone-Based Support Apps Add Value to the Treatment of Opioid Use Disorder?	30
The Association of Childhood Maltreatment and Mental Health Problems: Partly Causal and Partly Due to Other Factors	30
When Will There Be Good News?	30
Setting the Record Straight on Long-Term Use, Dose Escalation, and Potential Misuse of Prescription Benzodiazepines	29
Differences in Social Determinants of Health Underlie Racial/Ethnic Disparities in Psychological Health and Well-Being: Study of 11,143 Older Adults	29
Racial and Ethnic Biases and Psychiatric Misdiagnoses: Toward More Equitable Diagnosis and Treatment	29
Psychological Support for Psilocybin Treatment: Reply to Letters on Our Commentary	29
Innovative Directions to Advance Mental Health Disparities Research	29
Beneath the Phenotypic Surface: Pleiotropy Shapes the Co-Occurrence of Alcohol Use Disorder and Psychopathology	29
Interindividual Differences in Cortical Thickness and Their Genomic Underpinnings in Autism Spectrum Disorder	28
Mortality Among Parkinson’s Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries	28
Harnessing the Power of Population Cohorts to Study the Relationship Between Endocrine-Metabolic Disorders and Depression	28
Psychiatric Diagnoses in Parents and Psychiatric, Behavioral, and Psychosocial Outcomes in Their Offspring: A Swedish Population-Based Register Study	28
A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability	28
Evaluating the Evidence for Brain-Based Biotypes of Psychiatric Vulnerability in the Acute Aftermath of Trauma	27
A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial	26
The Amygdala and Depression: A Sober Reconsideration	26
Auditory Steady-State Responses Probe GABA-Related Oscillatory Cortical Circuits and Their Relation to Neurodevelopmental Mental Disorders	26
2024 Articles of Import and Impact	25
Correction	25
Ketamine After Two Antidepressants?	25
Guilt by Association: Inflammation and Shared Genetic Risk Between Stress-Related and Immune Disorders	25
Recommendations for the Usage of Ketamine and Esketamine	24
Understanding the Effects of Combined Lisdexamfetamine and Cognitive Behavior Therapy for Adults With Binge Eating Disorder	24
Highlights From the Residents’ Journal: December 2024	24
Progress and Challenges in GxE Research on Depression	24
Neuromelanin-Sensitive MRI: A Biomarker for Treatment-Resistant Schizophrenia?	24
Drugs and Addiction Science: NIDA Celebrates 50 Years of Research and Looks to the Future	23
Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg	23
Meta-Analyses of Genome-Wide Association Studies for Postpartum Depression	23
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial	23
Longitudinal Trajectory of the Link Between Ventral Striatum and Depression in Adolescence	23
Functional Connectivity Mapping for rTMS Target Selection in Depression	23
Associations Between General and Specific Mental Health Conditions in Young Adulthood and Cardiometabolic Complications in Middle Adulthood: A 40-Year Longitudinal Familial Coaggregation Study of 672,	23
Technology and Mental Health: State of the Art for Assessment and Treatment	22
Cannabis Use and the Endocannabinoid System: A Clinical Perspective	22
Current and Future Approaches to Pediatric Anxiety Disorder Treatment	22
Converging Evidence for Frontopolar Cortex as a Target for Neuromodulation in Addiction Treatment	21
Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy	21
Rethinking the First Episode of Schizophrenia: Identifying Convergent Mechanisms During Development and Moving Toward Prediction	20
Can Two 90-Minute Workshops Reduce Risk of Substance Use Disorder for Vulnerable Seventh Graders? Results and Scalability From the Co-Venture Trial	20
Auditory Oddball Responses Across the Schizophrenia-Bipolar Spectrum and Their Relationship to Cognitive and Clinical Features	20
Vaccines as Immunotherapies for Substance Use Disorders	20
Prevalence and Penetrance of Rare Pathogenic Variants in Neurodevelopmental Psychiatric Genes in a Health Care System Population	20
Understanding the Efficacy and Mechanism of Action of a Dextromethorphan-Bupropion Combination: Where Does It Fit in the NMDA Versus mu-Opioid Story?	20
Psychotropic Drug–Related Weight Gain and Its Treatment	20
Does Xanomeline/Trospium Have Unique Benefits for Cognitive Impairment Associated With Schizophrenia? Response to Tandon	20
Perinatal Mental Health: Advances and Opportunities	20
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research	20
Neglect of Adverse Effects in Treatment Guidelines for Depression	19
Recapitulation of Perturbed Striatal Gene Expression Dynamics of Donors’ Brains With Ventral Forebrain Organoids Derived From the Same Individuals With Schizophrenia	19
Highlights From the Residents’ Journal: September 2023	19
Late-Life Depression, Antidepressant Treatment, and Cognition: The Short Haul and the Long Haul	19
Pathogenic Variants and Ascertainment: Neuropsychiatric Disease Risk in a Health System Cohort	19
Antidepressants and Bipolar Disorder: The Plot Thickens	19
Varenicline as a First-Line Treatment for Individuals With Current Major Depressive Disorder Who Smoke Cigarettes	18
Effects of County-Level Opioid Dispensing Rates on Individual-Level Patterns of Prescription Opioid and Heroin Consumption: Evidence From National U.S. Data	18
An Insula-Enriched Regulator of Retinoic Acid Marks a New Intersection in the Neural Circuitry of Mouse Social Behavior	18
Putting Genetics to Work in the Psychiatric Clinic	18
Improved Response Inhibition Through Cognition-Guided EEG Neurofeedback in Men With Methamphetamine Use Disorder	18
Focusing on Substance Use Disorders, Opioids, and Craving	18
Estimating Multimodal Structural Brain Variability in Schizophrenia Spectrum Disorders: A Worldwide ENIGMA Study	18
Clozapine’s High Incidence of Ileus and Pneumonia Demand Better Clinical Strategies—How Do We Get There?	17
Increased Inflammation in Depression: A Little in All, or a Lot in a Few?	17
Irremediable Psychiatric Suffering, a Potential Indication for Psilocybin Treatment	17

Intermittent Theta Burst Stimulation With Adjunctive D-Cycloserine for Obsessive-Compulsive Disorder: A Randomized Clinical Trial	17
Don’t Throw the Baby Out With the Bathwater: A Need for Nuanced Practice and Additional Research on Telehealth Management of ADHD	17
Polygenic Risk Scores and Genetics in Psychiatry	17
Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder	17
Neuropsychiatric Symptoms of Subacute and Chronic Long COVID	17
The Devastating Clinical Consequences of Child Abuse and Neglect: Increased Disease Vulnerability and Poor Treatment Response in Mood Disorders	17
Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia	16
MORE Is Less Pain and Less Opioid Misuse: A Mindful Remedy	16
Highlights From the Residents’ Journal: June 2025	16
Beyond the Landmarks: Where to Next With Biomarkers of Autism?	16
Reports to the Membership	16
Intergenerational Effects of the Fast Track Intervention on Next-Generation Child Outcomes: A Preregistered Randomized Clinical Trial	16
Clozapine, Long-Acting Injectables (and Polypharmacy?) Superior in U.S. and International Registries	16
Disclosure of Editors’ Financial Relationships	16
Association Between Polygenic Risk Scores and Outcome of ECT	16
Affective Disorders, Pharmacogenomics, and Psychiatric Illness-Related Cardiometabolic Problems	16
Treating Depression With Repetitive Transcranial Magnetic Stimulation: A Clinician’s Guide	15
Psychosis Risk With Prescription Amphetamine	15
MDMA and MDMA-Assisted Therapy	15
The Intergenerational Impact of Structural Racism and Cumulative Trauma on Depression	15
Xanomeline-Trospium Treatment of Cognitive Impairments of Schizophrenia: Hope for Some, or Hope for All?	15
An Honest Reckoning With the Amygdala and Mental Illness	15
New Insights Into Major Depression and the Treatment of Bipolar Depression	15
Real-World Evidence on Clinical Outcomes of Commonly Used Antidepressants in Older Adults Initiating Antidepressants for Depression: A Nationwide Cohort Study in Denmark	15